**5. Conclusions**

A perfect anticoagulant would prevent thrombosis without inducing systemic hypocoagulation, and would prevent undesired bleeding complications. Thus, an FXa inhibitor could potentially have the properties of a desirable anticoagulant. In the search for new anticoagulant drugs, the serine protease FXa is a particularly promising target and has attracted a strong interest over the last 15 years.

Development of DOACs such as direct FXa inhibitors is an important innovation in the anticoagulation drug discovery field. In spite of widespread knowledge about the clotting mechanism, its complexity generates significant challenge for the investigation and production of innovative anticoagulants that are both efficient and safe. DOACs availability embraces a vast field of the clinical health system for prevention of diverse pathologies. Currently, with the development and approval of DOACs such as FXa inhibitors, clinical health professionals can use these novel therapeutics approaches.

The continuous and future development of an innovative oral anticoagulant drug that is designed to prevent several thrombotic disorders and related pathologies would be of remarkable wide-reaching health value.
